Warts refer to non-cancerous skin growths that can appear as small lumps on the genitals, face, hands, and feet. It is caused by viruses called human papillomaviruses (HPV). Warts are prevalent among children and teenagers, with various studies suggesting that nearly 33% of this population is affected by warts. Thus, the increasing cases and high recurrence rates of warts are augmenting the demand for more effective and long-lasting wart treatments.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing warts pipeline development activities.
Treatment primarily focuses on removing warts, preventing recurrence, and addressing underlying HPV infections. Salicylic acid, available in the form of over-the-counter (OTC) gels, patches, or solutions, is commonly used as a topical treatment in mild cases. Other warts therapeutics include immunotherapy such as Candida antigen or interferon to stimulate the immune system to target the wart. Further, the growing focus on gene-based therapies and therapeutic vaccines is anticipated to support pipeline expansion in the near future.
Both men and women are almost equally affected by warts. In Whites, the condition is more common compared to Blacks or Asians. Warts are also prevalent among immunosuppressed people and meat handlers.
Drug: Candin (Intradermal Solution)
Sponsored by Nielsen BioSciences, Inc., the objective of this randomized, double-blinded, clinical trial is to investigate the efficacy and safety of candin for the treatment of Verruca Vulgaris (common warts) in adolescents and adults. The study is under Phase III clinical development and has an estimated 330 participants.
This product will be delivered within 3-5 business days.
Report Coverage
The Warts Drug Pipeline Insight Report by the publisher gives comprehensive insights into warts therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Warts. The warts report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The warts pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with warts treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing warts pipeline development activities.
Warts Drug Pipeline Outlook
Warts are small, fleshy growths that can develop on the skin and inside the mouth. They can differ in appearance and are often round, flat, or smooth. Various strains of human papillomavirus (HPV) can cause warts. Common warts, plantar warts, flat warts, and genital warts are some of the types of warts._x000D__x000D_Treatment primarily focuses on removing warts, preventing recurrence, and addressing underlying HPV infections. Salicylic acid, available in the form of over-the-counter (OTC) gels, patches, or solutions, is commonly used as a topical treatment in mild cases. Other warts therapeutics include immunotherapy such as Candida antigen or interferon to stimulate the immune system to target the wart. Further, the growing focus on gene-based therapies and therapeutic vaccines is anticipated to support pipeline expansion in the near future.
Warts Epidemiology
Warts are a common medical condition, affecting around 10% of the population . It can occur at any age, with a high prevalence found among school-aged children. However, it is rare in infancy and early childhood.Both men and women are almost equally affected by warts. In Whites, the condition is more common compared to Blacks or Asians. Warts are also prevalent among immunosuppressed people and meat handlers.
Warts - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of warts drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The warts report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Biologics
- Nucleic Acid-Based Molecules
- Natural Extracts and Phytochemicals
- Peptides-Based Molecules
- Others
By Route of Administration
The Warts report assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Warts Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with a substantial number of warts emerging drugs undergoing clinical development.Warts Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under warts pipeline analysis include small molecules, biologics, nucleic acid-based molecules, natural extracts and phytochemicals, peptides-based molecules, and others. The warts report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for warts.Warts Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the warts drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed warts therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in warts clinical trials:- Merck Sharp & Dohme LLC
- Nielsen BioSciences, Inc.
- Veradermics, Inc.
- Labo'Life
- Shanghai Bovax Biotechnology Co., Ltd.
- X4 Pharmaceuticals
Warts Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for warts. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of warts drug candidates.Drug: Candin (Intradermal Solution)
Sponsored by Nielsen BioSciences, Inc., the objective of this randomized, double-blinded, clinical trial is to investigate the efficacy and safety of candin for the treatment of Verruca Vulgaris (common warts) in adolescents and adults. The study is under Phase III clinical development and has an estimated 330 participants.
Drug: 2LVERU® or 2LVERU® JUNIOR
Labo'Life is conducting a Phase IV placebo-controlled, double-blind study aimed at examining the efficacy and safety of Warts drug candidates 2LVERU® JUNIOR and 2LVERU®. The interventional study has enrolled about 162 patients and is expected to be completed by March 2027.Reasons To Buy This Report
The Warts Pipeline Insights provides a strategic overview of the latest and future landscape of treatments for warts. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities provided by warts drug report.Key Questions Answered in the Warts - Pipeline Insight Report
- What is the current landscape of warts pipeline drugs?
- Which companies/institutions are developing warts therapeutic drugs?
- How many phase II drugs are currently present in warts pipeline drugs?
- Which company is leading the warts pipeline development activities?
- What is the current warts commercial assessment?
- What are the opportunities and challenges present in the warts drug pipeline landscape?
- What is the efficacy and safety profile of warts pipeline drugs?
- Which companies/institutions are involved in warts collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What geographies are covered for clinical trials in warts?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Warts
4 Patient Profile: Warts
5 Warts: Epidemiology Snapshot
6 Warts: Market Dynamics
7 Warts: Key Facts Covered
8 Warts, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Warts Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Warts Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Warts Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Warts Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Warts, Key Drug Pipeline Companies
